Anti-HBV antiviral prophylaxis
Phase 3Small molecule
Anti-HBV antiviral prophylaxis is one of 30 small molecule programs targeting Hepatitis B. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
252 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Viread
GileadPhase 3
YF-Vax
SanofiPhase 3
Immunoglobulins
CSL BehringPhase 3
Recombinant Hepatitis B Vaccine
NovartisPhase 3
Hydronidone
BBeijing Continent Pharmaceutical Co, Ltd.
Phase 3
Hepatitis B Adjuvanted Vaccine
GSKPhase 3
HEPLISAV
DDynavax Technologies Corporation
Phase 3
Vemlidy
GileadPreclinical
HB-AS02V
HHenogen
Phase 3
HBVAXPRO Vaccine
HHenogen
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatitis B1 trial
Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection
Active, not recruiting·IInstitut de Recherche pour le Developpement·Phase 3·NCT03343431·504 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details